reason report
zanu miss consensu us off-set strong tisl launch
earn reiter key program timelin brukinsa
zanubrutinib sale miss consensu estim us
versu align forecast
believ consensu number may anticip off-label
chronic lymphocyt leukemia cll revenu similar astrazeneca
azn op calquenc initi launch mantl cell lymphoma
mcl gener sale
initi launch quarter mark signific sale cll
estim assum off-label cll penetr given avail
imbruvica calquenc altern patient intoler
imbruvica bgne also report tislelizumab sale china
significantli beat consensu estim manag
indic inordin amount inventori build
drive beat given result taper brukinsa
launch reflect competit dynam us maintain
peak estim drug also increas estim
china may start becom signific compon
bgne invest thesi opportun china becom
tangibl market continu evolv
total revenu beat expect driven tislelizumab sale
china total revenu beat consensu expect
visibl alpha driven better expect sale
tislelizumab china off-set lower anticip
sale brukinsa bristol collaboration-rel revenu
decreas prior year driven
neg covid impact gener competit abraxan sale
suspens china
brukinsa key clinic develop remain track compani
compar brukinsa versu bendamustin rituximab treatment-nav
cll/sll patient remain track alpin trial compar
brukinsa imbruvica patient r/r cll/sll expect
complet enrol compani plan present detail
phase aspen data waldenstrm macroglobulinemia wm patient
asco virtual meet also approach regulatori
agenc discuss feasibl includ data indic
label despit fail trial remind per note
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil bgne
compani inform svb leerink llc research
revenu million
pleas refer page import disclosur price chart analyst certif
trial fail show well-differenti profil brukinsa
meet statist signific imbruvica control arm
outperform compani also expect brukinsa approv china
r/r mcl cll/sll applic delay
complet manufactur inspect recent focu chines
author brukinsa also studi patient
hospit pulmonari distress
tislelizumab program also remain track despit covid
tislelizumab non-squam non-smal cell lung cancer
nsclc trial may form basi
chines snda submiss earli compani expect
announc top-lin result global phase trial compar
tislelizumab versu docetaxel nsclc patient well data
phase trial compar tislelizumab versu chemotherapi
chang model adjust model follow
result specif taper brukinsa launch us
eu maintain peak assumpt drug believ
compani abl success penetr us market given
differenti safeti toler profil littl off-
label cll usag formal approv drug obtain
also increas market share tislelizumab china result
peak sale previous bgne share
may experi pressur follow brukinsa miss initi
launch quarter believ difficult extrapol earli result
mantl cell launch much larger cll opportun also
believ chines compon bgne invest thesi
may eventu prove valuabl contempl
maintain op rate pt
rate beigen bgne share outperform pt beigen commerci
stage biotechnolog compani number commerci drug licens celgen
market china approv btk inhibitor brukinsa well pipelin
development asset brukinsa zanubrutinib differenti btk inhibitor
develop b-cell malign recent receiv fda approv treatment r/r
mantl cell lymphoma mcl target b-cell pathway btk drug transform
chronic lymphocyt leukemia cll diseas patient die
caus rather malign howev toler issu often result patient stop
therapi ibrutinib beigen brukinsa appear much larger therapeut
window fewer advers event see drug multi-blockbust asset beigen
also develop antibodi tislelizumab purport benefit maintain
higher resist mechan allow tumor circumv blockad given
drug modifi fc region impact role macrophag resist
third prong beigen invest thesi deriv parp inhibitor opportun
gastric cancer one think larg ignor investor follow
disappoint class ovarian cancer well fail lynparza trial gastric
cancer drug subtherapeut dose still provid signal activ
importantli beigen forefront chines biotechnolog effort believ
compani like signific home player advantag versu multi-n
corpor china thesi support global oncolog
develop deal includ equiti stake bgne provid access
three commerci product develop stage compound provid signific
valid beigen stori view
use risk-adjust sum-of-the-part methodolog valu beigen deriv pt
examin clinic regulatori commerci risk opportun
individu indic region assign probabl success account
likelihood achiev revenues/expens risk-adjust sum-of-the-part
analysi appli discount rate cash flow gener beigen
asset determin total net present valu risk-adjust asset total npv
reflect remain clinic regulatori risk program
clinic risk clinic trial failur beigen pipelin asset especi later
stage drug includ zanubrutinib tislelizumab pamiparib
commerci risk greater anticip competit either domest china
intern could impact perceiv valu beigen pipelin
regulatori risk failur obtain regulatori approv compani product
unit state europ china would like diminish valu beigen pipelin
productpeak revenu mn phase developmentnpv bgne mn probabl successrisk-adjust npv mn expect launchnet current valu share us/eu zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk zanubrutinib btk tislelizumab tislelizumab pamiparib parp pamiparib parp ovarian product china product china pipelin drug discoveri asset count risk-adjust equiti valu risk zanubrutinib btk cllchina zanubrutinib btk cllus/eu zanubrutinib btk mclus/eu zanubrutinib btk wmus/eu zanubrutinib btk mzlchina zanubrutinib btk mcl/mzl/wmus/eu zanubrutinib btk flchina zanubrutinib btk flus/eu tislelizumab revenuechina tislelizumab revenueww pamiparib parp gastricchina pamiparib parp ovarian cancerbristol product china collaborationamgen product china collaborationearli pipelin drug discoveri platformresidu beigen ltd
companyprogram/drugtherapeut areaeventtimingev typetri phasebeigenezanubrutiniblymphomapotenti chines approv r/r mcl r/r pivot phii china trial china nda trial dataphiibeigenezanubrutinibwaldenstrom sdetail data phiii aspen trial zanubrutinib vs imbruvica r/r wm trial dataphiiibeigenezanubrutinibwaldenstrom sregulatori discuss fda ema aspen carcinomaphii data tislelizumab global trial r/r trial dataphiibeigenetislelizumabnon-smal cell lung cancersubmit snda phiii china trial non-squam lymphocyt leukemiadata phiii sequoia trial zanubrutinib vs br tn cll patient inelig trial dataphiiibeigenepamiparibovarian cancerdata phiii mainten trial pamiparib plat sensit ovarian cancer trial dataphiiibeigenepamiparibovarian cancerphii china data ovarian trial dataphiibeigenetislelizumabesophag carcinomadata phiii trial tislelizumab vs physician choic chemo esophag earli trial dataphiiibeigenetislelizumabnon-smal cell lung cancerdata phiii trial tislelizumab vs docetaxel earli trial dataphiiibeigenezanubrutinibchron lymphocyt leukemiapotenti data alpin trial zanubrutinib vs ibrutinib r/r trial dataphiiibeigen catalyst beigen ltd
beigen mn except ep
amort intang asset
net loss attribut non-controlling interest
net incom loss attribut bgne
bs cf mn
svb leerink estim compani file
